Publication & Editorial Policy
AIMS AND SCOPE
Journal of Pharmacovigilance & Drug Safety is a peer-reviewed open-access international medical research journal that publishes original research work in the form of Full Length Papers, Review Articles, Case Reports, Letter to Editor, Short communications, Drug Updates. The journal is printed Two times a year. The language of the journal is English.
Journal of Pharmacovigilance & Drug Safety aims to provide a home for all properly conducted medical research to be fully reported, after a rigorous and transparent peer review process. The journal carries the charges for publication of manuscripts.
The journal is based on independent and unbiased double-blinded peer-reviewed principles. Only unpublished papers that are not under review for publication elsewhere can be submitted. The authors are responsible for the scientific content of the material to be published. Journal of Pharmacovigilance & Drug Safety reserves the right to request any research materials on which the paper is based.
Journal of Pharmacovigilance & Drug Safety encourages and enables academicians, researchers, specialists and primary care physicians to publish their valuable research in all branches of medicine. The primary aim of the journal is to publish original articles with high scientific and ethical quality and serve as a good example of medical publications in the World.
The Editorial Board of the Journal of Pharmacovigilance & Drug Safety and the Publisher adheres to the principles of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the US National Library of Medicine (NLM), the World Medical Association (WMA), the US Office of Research Integrity (ORI), the European Association of Science Editors (EASE), and the International Society of Managing and Technical Editors (ISMTE).
All the articles are available in PDF format on our website (www.journalofsopi.com) and can be downloaded free of charge.
Journal’s mission is to distribute and expand medical data to the World as well as build a supportive and vibrant community of scholars to connect and explore ideas by publishing articles related to all fields of medicine. In addition to the educational material and links available on the journal’s webpage, Journal of Pharmacovigilance & Drug Safety Editorial Board has also been organizing educational meetings on the subjects of medical research, writing, and scientific ethics.
Journal of Pharmacovigilance & Drug Safety believes that quality and ethical research and publication will lead to the progress of medical sciences and healthcare worldwide.
Journal of Pharmacovigilance & Drug Safety is committed to the highest standards of research and publication ethics and does not allow any form of plagiarism. All submitted manuscripts are screened with plagiarism software at least two times during the evaluation process to detect instances of overlapping and similar text. High similarity scores even more than 10% may lead rejection of a manuscript even after acceptance. The editors will act in accordance with the relevant international rules of publication and research ethics (COPE guidelines, WAME resources, WMA policies, and ORI) if any ethical misconduct is suspected.
In accordance with the journal's policy, an approval of research protocols by an ethics committee in accordance with international agreements “WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects (last updated: October 2013, Fortaleza, Brazil)” , "Guide for the care and use of laboratory animals (8th edition, 2011)" and/or “International Guiding Principles for Biomedical Research Involving Animals (2012)” is required for all experimental, clinical and drug trial studies. For articles concerning experimental research on humans, a statement should be included that shows informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. The journal may request a copy of the Ethics Committee Approval received from the relevant authority. Informed consent must also be obtained for case reports.
CONFLICT OF INTEREST POLICY
Journal of Pharmacovigilance & Drug Safety editorial review process is in accordance with the Good Editorial Practice set by international editorial organizations (WAME, COPE). WAME indicates that “conflict of interest exists when an author, reviewer, or editor in the publication process (submission of manuscripts, peer review, editorial decisions, and communication between authors, reviewers, and editors) has a competing interest that could unduly influence his or her responsibilities (academic honesty, unbiased conduct and reporting of research, and integrity of decisions or judgments) in the publication process”.
Journal of Pharmacovigilance & Drug Safety requires that each author, reviewer, and editor must disclose to the editor-in-chief any conflict of interest related to family, personal, financial, political, or religious issues as well as any competing interest outlined above at the WAME’s definition. Whether or not a conflict of interest and financial support exist, they must be declared at the Conflict of Interest Statement as well as at the end of the manuscripts. If a reviewer or an editor has a conflict of interest and/or believes that it is not appropriate to be a reviewer or an editor for a given manuscript, the reviewer or the editor should resign from the assignment. The Editorial Board members of the Journal of Pharmacovigilance & Drug Safety, who handle submissions and recommend decisions to the Editor in chief may also submit their own manuscripts to the journal as all of them are active researchers and scientists. However, they cannot take place at any stage on the editorial decision of their manuscripts in order to minimize any possible bias. They will be treated like any other author, and if any, final acceptance of such manuscripts can only be made by the positive recommendation of at least two external reviewers, who are not the members of decision-making Editorial Board.
Authors should not contact any of the editors during the review process. All necessary information regarding the process of a manuscript can be obtained from the editorial office. However, the names of the handling editor and the reviewers are not given to the author(s). Due to the Journal’s double-blinded review principles, the names of authors and reviewers are not known to each other.
Subscriptions/Permissions and Reprints/Advertisements
Free full-text articles can be accessed from the following link: www.journalofsopi.com; with no charge. Applications for subscriptions, permissions, reprints and advertisements should be made to the following addresses.
All opinions and reports within the articles that are published in the Journal of Pharmacovigilance & Drug Safety are the personal opinions of the authors. The Editors, the publisher and the owner of the journal of Pharmacovigilance & Drug Safety do not accept any responsibility for these articles.